European healthcare policies for controlling drug expenditure

PharmacoEconomics

Volumn 21, Issue 2, 2003, Pages 89-103

  Ess, Silvia M ^a,d   Schneeweiss, Sebastian ^b,c   Szucs, Thomas D ^a  

^a Hirslanden Research   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d Hirslanden Research   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BUDGET; CONSUMER; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG USE; DRUG UTILIZATION; EUROPE; GOVERNMENT; HEALTH CARE POLICY; LICENSING; MEDICAL PRACTICE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; PROSPECTIVE PRICING; REVIEW;

COST CONTROL; COST SHARING; DRUG AND NARCOTIC CONTROL; DRUG COSTS; DRUG INDUSTRY; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; EUROPE; FEMALE; FORMULARIES; GUIDELINES; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS;

EID: 0037239005     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321020-00002     Document Type: Review

References (52)

1. Laurence C. Opening statement, in health care reforms: the will to change, OECD, editor. Paris: Directorate for Education, Employment and Social Affairs, 1996
2. OECD, The reform of health care systems: a review of seventeen OECD countries. 1st ed. Health Policies Studies. Paris: OECD, 1994
3. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Paris: OECD, 2000
4. Louis WJ. Regulatory demands for cost-benefit studies. Am Heart J 1990; 119 (3): 771-5
5. Jönsson B. Cost sharing for pharmaceuticals - the Swedish Reimbursement System. Pharmacoeconomics 1996; 10 Suppl. 10: 68-74
6. Gerdtham U-G, Johannesson M, Gunnarsson B, et al. The effect of shanges in treatment patterns on drug expenditure. Pharmacoeconomics 1998; 13 (1 Pt 2): 127-34
7. OECD health data 1999. Software package: a comparative analysis of 29 countries. Paris: OECD, 1999
8. OECD health data 2000. Software package: a comparative analysis of 29 countries. Paris: OECD, 2000
9. OECD health data 2001. Software package: a comparative analy'sis of 29 countries. Paris: OECD, 2001
10. Klein R. Puzzling out priorities. Why we must acknowledge that rationing is a political process. BMJ 1998; 317:959-60
11. Walley T, Earl-Slater A, Haycox A, et al. An integrated national pharmaceutical policy for the United Kingdom? BMJ 2000; 321: 1523-6
12. Jönsson B. Pricing and reimbursement of pharmaceuticals in Sweden. Pharmacoeconomics 1994; 6 Suppl. 1: 51-60
13. Rovira J. Are national drug expenditure control policies compatible with a single European market? Pharmacoeconomics 1996: 10 Suppl. 2: 4-13
14. Earl-Slater A. The importance of the pharmaceutical industry to the UK economy. J Manag Med 1998: 12 (1): 5-20
15. Dickson M. The pricing of pharmaceuticals: an international comparison. Clin Ther 1992: 14 (4): 604-11
16. Abbott TA. Price regulation in the pharmaceutical industry: prescription or placebo? J Health Econ 1995 14 (5): 551-67
17. Dickson M, Redwood H. Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 1998: 14 (5): 471-9
18. Schwabe U, Paffrath D. Arzneimittelverordnungs - report 2001. Berlin: Springer, 2001
19. Giuliani G, Selke G, Garattini L. The German experience in reference pricing. Health Policy 1998: 44: 73-85
20. Schneeweiss S, Schöffski O, Selke GW. What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution? Health Policy 1998; 44: 253-60
21. Rigter H. Recent public policies in the Netherlands to control pharmaceutical pricing and reimbursement. Pharmacoeconomics 1994; 6 Suppl. 1: 15-21
22. Lockhart-Mirams A. Pharmaceutical price regulation in the UK. Der Internist 2000; 41 (5): M111-4
23. Feely J. The influence of pharmacoeconomic factors on prescribing patterns in Ireland. Pharmacoeconomics 1992; 2 (2): 99-106
24. Danzon PM. Pharmaceutical price regulation. National policies versus global interest. Washington DC: American Enterprise Institute Press, 1997
25. Gutachten des Sachverständigenrates für die Konzertierten Aktion im Gesundheitswesen 2000-2001: Zur Steigerung von Efflzienz und Effektivität der Arzneimittelversorgung in der gesetzlichen Krankenversicherung. Available from URL: http://www.svr-gesundheit.de/gutacht/gutalt/gutaltle.htm [Accessed 2001 Dec 20]
26. Fattore G, Jommi C. The new pharmaceutical policy in Italy. Health Policy 1998; 46: 21-41
27. Le Pen C. Drug pricing and reimbursement in France. Pharmacoeconomics 1996: 10 Suppl. 2: 26-36
28. Marino M, Marqués J, Velasco A. Impact of selective financing of drugs on pharmaceutical expenditure control in the Province of Valladolid, Spain. Pharmacoeconomics 1996; 10 (3): 269-80
29. Soumerai SB, Ross-Degnan D, Gortmaker S, et al. Withdrawing payment for nonscientific drug therapy: intended and unexpected effects of a large-scale natural experiment. JAMA 1990: 263: 831-9
30. Cranovsky R, Schilling J, Faisst K et al. Health technology assessment in Switzerland. Int J Technol Assess Health Care 2000 Spring; 16 (2): 576-90
31. Harris B, Stergachis A, Ried L. The effects of drug co-payments on utilisation and cost of pharmaceuticals in a health maintenance organisation. Med Care 1990: 28: 901-17
32. Soumerai S, McLaughlin TJ, Ross-Degnan D, et al. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med 1994: 331: 650-5
33. Soumerai S, McLaughlin TJ, Ross-Degnan D, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. N Engl J Med 1991: 325: 1072-7
34. Soumerai S, Avorn J, Ross-Degnan D, et al. Payment restrictions for prescriptions drugs under Medicaid. N Engl J Med 1987; 317: 550-6
35. Schneeweiss S, Walker AM, Glynn RJ, et al. Outcomes of reference drug pricing for angiotensin-converting enzyme inhibitors in British Columbia, Canada. N Engl J Med 2002; 346 (11): 822-9
36. Greenhalgh T, Gill P. Pressure to prescribe. BMJ 1997: 315: 1482-3
37. Bradley C. Uncomfortable prescribing decisions: a critical incident study. BMJ 1992: 304: 294-6
38. Wensing M, Grol R. Single and combined strategies for implementing changes in primary care: a literature review. Int J Qual Health Care 1994: 6: 115-32
39. Oxman AD. No magic bullets: a systematic review of 102 trials of interventions to improve professional practice. Can Med Assoc J 1995: 153: 1423-31
40. Amstrong D, Reyburn H, Jones R. A study of general practitioner's reasons for changing their prescribing behaviour. BMJ 1996; 312: 942-52
41. McKee M, Clarke A. Guidelines, enthusiasms, uncertainty and the limit to purchasing. BMJ 1995: 310: 101-4
42. West E, Newton J. Clinical guidelines. BMJ 1997; 315: 324
43. Pelc A, Castan J-P. New developements in pricing and drug reimbursement in France. Pharmacoeconomics 1994; 6 Suppl. 1: 28-35
44. Schulenburg JM, Uber A. Current issues in German healthcare. Pharmacoeconomics 1997; 12 (5): 517-23
45. Stewart-Brown S, Surender R, Bradlow J, et al. The effects of fundholding in general practice on prescribing habits three years after the introduction of the scheme. BMJ 1995; 311: 1543-7
46. O'Connell D, Henry D, Tomlins R. Randomised controlled trial of effect of feedback on general practitioners' prescribing in Australia. BMJ 1999; 318: 507-11
47. Delnoij D, Brenner G. Importing budget systems from another countries: what can we learn fro the German drug budget and the British GP fundholding. Health Policy 2000; 52: 157-69
48. Schöffski O. Consequences of implementing a drug budget for office-based physicians in Germany. Pharmacoeconomics 1996; 10 Suppl. 2: 37-47
49. Ulrich V, Wille E. Healthcare reform and expenditure on drugs: the German situation. Pharmacoeconomics 1996; 10 Suppl. 2: 81-8
50. Baines DL, Parry DJ. Analysis of the ability of the new needs adjustment formula to improve the setting of weighted capitation prescribing budgets in English genereal practice. BMJ 2000; 320: 288-90
51. Harris CM, Scrivener G. Fundholder's prescribing costs: the first five years. BMJ 1996; 313: 1531-4
52. Dixon J, Mays N. New Labour, new NHS? BMJ 1997; 315: 1639-40